MediWound to launch Phase III trial for venous leg ulcers
MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it ...
BioLab Holdings, Inc. Receives IRB Approval for Trial on Membrane Wrap™
BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in wound healing and wound care products, is pleased to announce the approval of its randomized control trial designed to ...
MediWound stock climbs 4% on Phase 3 study initiation
MediWound (NASDAQ:MDWD) stock climbed 4% following news that the company has initiated a Phase 3 study of its wound care product EscharEX in the treatment of venous leg ulcers, or VLU. The company ...
MediWound Ltd.: MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...
MediWound Initiates the VALUE Global Phase III Pivotal Trial of EscharEx® for Treatment of Venous Leg Ulcers
Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure ...
hospitalnews2d
Alcohol-related deaths up 18% during pandemic
Alcohol-related deaths increased 18% during the pandemic, as did hospitalizations related to alcohol use, according to new ...
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting
Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.